June 3, 2011
/PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients. The data were presented by the principal investigator for the study, Dr.
Ursula A. Matulonis
, medical director of gynecologic oncology at Dana-Farber Cancer Institute and associate professor of medicine,
Harvard Medical School
, during a poster discussion session at the American Society of Clinical Oncology (ASCO) Annual Meeting being held
June 3 - 7, 2011
The trial was an open-label, single-arm, multi-center-study of ENMD-2076 dosed orally as a single agent in patients with platinum-resistant recurrent ovarian, peritoneal or tubal cancer. The study was conducted at six sites in
the United States
and included Dana-Farber Cancer Institute,
Melvin & Bren Simon Cancer Center,
University of Chicago
Medical Center, Memorial Sloan-Kettering Cancer Center,
University of Colorado
Cancer Center, and Princess Margaret Hospital. Sixty-four patients were enrolled of which 57 were evaluable at the time of the presentation. The primary endpoint for the study was progression-free survival rate at six months. Secondary end-points include response rate, duration of response, and overall survival.
ENMD-2076 demonstrated clinical activity when administered daily orally as a single agent. Interim data from 57 evaluable patients showed a six-month progression free survival rate of 19%. Of the evaluable patients, four patients achieved a partial response and 30 patients achieved stable disease as measured by RECIST v1.1. Median overall survival has not yet been reached. The side effect profile was consistent with activity against ENMD-2076's targets, in particular, VEGFR2 and Aurora A. Studies to evaluate potential markers of ENMD-2076 in this patient group are ongoing.